Showing results (1-10 of 97) with videos related to
Sort By:
Pageof 10
Human Gene Therapy|June 27, 2020
CRISPR/Cas9 Editing: Sparking Discussion on Safety in Light of the Need for New TherapeuticsTiffany M Carlaw, Lin-Hua Zhang, Colin J D RossJournal of Autoimmunity|April 10, 2007
Pharmacogenomics and its implications for autoimmune diseaseColin J D Ross, Hagit Katzov, Bruce Carleton, et al.Therapeutic Drug Monitoring|September 12, 2024
Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping ReviewAngela Wu, Edward J Raack, Colin J D Ross, et al.Therapeutic Drug Monitoring|February 2, 2023
Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced CardiotoxicityAngela Siemens, Shahrad Rod Rassekh, Colin J D Ross, et al.Annual Review of Pharmacology and Toxicology|October 2, 2020
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical SettingsWan-Chun Chang, Reo Tanoshima, Colin J D Ross, et al.Frontiers in Genetics|March 6, 2015
Use of pharmacogenomics in pediatric renal transplant recipientsMara Medeiros, Gilberto Castañeda-Hernández, Colin J D Ross, et al.Current Opinion in Pediatrics|August 16, 2020
Prevention of adverse drug effects: a pharmacogenomic approachErika N Scott, Jafar S Hasbullah, Bruce C Carleton, et al.Physical Therapy|August 3, 2013
Promoting neuroplasticity for motor rehabilitation after stroke: considering the effects of aerobic exercise and genetic variation on brain-derived neurotrophic factorCameron S Mang, Kristin L Campbell, Colin J D Ross, et al.Paediatric Drugs|March 27, 2013
Cancer pharmacogenomics in children: research initiatives and progress to dateShahrad Rod Rassekh, Colin J D Ross, Bruce C Carleton, et al.Bioinformatics (Oxford, England)|June 23, 2018
HUME: large-scale detection of causal genetic factors of adverse drug reactionsMehrdad Mansouri, Bowei Yuan, Colin J D Ross, et al.Pageof 10